Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 8788 results

  1. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    In development Reference number: GID-TA11565 Expected publication date: TBC

  2. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

  3. Neuromodulation for chronic pelvic pain

    Topic prioritisation

  4. Transcatheter valve-in-valve implantation for the treatment of Tricuspid valve

    Topic prioritisation

  5. Endovascular Arch Repair

    Topic prioritisation

  6. Endovascular stent insertion for intracranial atherosclerotic disease

    Topic prioritisation

  7. Subcutaneous nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID 12178]

    Topic prioritisation

  8. Cor-Knot for tying suture knots in valve surgery

    Topic prioritisation

  9. Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]

    Topic prioritisation

  10. Heart valve disease presenting in adults: investigation and management - transcatheter aortic valve implantation (TAVI) to treat aortic stenosis (update)

    In development Reference number: GID-NG10457 Expected publication date: TBC

  11. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

  12. Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]

    Awaiting development Reference number: GID-TA11813 Expected publication date: TBC

  13. Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]

    Awaiting development Reference number: GID-TA11751 Expected publication date: TBC